INTRODUCTION:
Programmed cell death occurs throughout life in all tissues of the body, and more than a billion cells die every day as part of normal processes. Thus, rapid and efficient clearance of cell corpses is a vital prerequisite for homeostatic maintenance of tissue health. Failure to clear dying cells can lead to the accumulation of autoantigens in tissues that foster diseases, such as chronic inflammation, autoimmunity, and developmental abnormalities. In the normal immune system, phagocytic engulfment of apoptotic cells is accompanied by induction of a certain degree of immune tolerance in order to prevent self-antigen recognition. Over the past few decades, enormous efforts have been made toward understanding various mechanisms of tumor suppressor p53-mediated apoptosis. However, the involvement of p53 in postapoptosis has yet to be addressed.
RATIONALE:
One of the most intriguing, yet enigmatic, questions in studying homeostatic control of efficient dead cell clearance and proper immune tolerance is how these two essential activities are interrelated: The complexity of these processes is demonstrated by the many receptors and signaling pathways involved in the engulfment of apoptotic cells and stringent discrimination of self antigens from nonself antigens. Thus, there must be key connection(s) linking the balance between immune homeostasis and inflammation. In addition to the antitumor functions of p53, p53 has been implicated in immune responses and inflammatory diseases, with various roles in the immune system becoming apparent. We identified a postapoptotic target gene of p53, Death Domain1a (DD1a), that is responsive to genotoxic stresses and expressed in immune cells. DD1a appears to function as an immunoregulator of T cell tolerance. We hypothesized that p53 controls signaling-mediated phagocytosis of apoptotic cells through its target, DD1a. We determined that DD1a functions as an engulfment ligand or receptor that is involved in homophilic intermolecular interaction at intercellular junctions of apoptotic cells and macrophages. We also addressed whether DD1a deficiency caused any defects in dead cell clearance in vivo.
RESULTS: DD1a has similarity with several members of the immunoglobulin superfamily with the extracellular immunoglobulin V (IgV) domain, such as TIM family proteins and an immune checkpoint regulator, PD-L1. We found that the p53 induction and maintenance of DD1a expression in apoptotic cells and its subsequent functional intercellular homophilic interaction between apoptotic cells and macrophages are required for engulfment of apoptotic cells. DD1a-deficient mice showed less reduction in organ size and cell number after ionizing radiation (IR), owing to defective dead cell clearance. DD1a-null mice are viable and indistinguishable in appearance from wildtype littermates at an early age. However, at a later age, DD1a deficiency resulted in the development of autoimmune phenotypes and prominent formation of immune infiltrates in the skin, lung, and kidney, which indicated an immune dysregulation and breakdown of selftolerance in DD1a-null mice. We demonstrated that DD1a also plays an important role as an intercellular homophilic receptor on T cells, which suggests that DD1a is a key-connecting molecule linking postapoptotic processes to immune surveillance. We found that DD1a deficiency in T cells impaired DD1a-mediated inhibitory activity of T cell proliferation. These data indicate that potential homophilic DD1a interactions are important for the DD1a-mediated T cell inhibitory role. Therefore, the results indicate a role for p53 in regulating expression of immune checkpoint regulators, including PD-1, PD-L1, and DD1a.
CONCLUSION:
We found that the tumor suppressor p53 controls signaling-mediated phagocytosis of apoptotic cells through its target DD1a, which suggests that p53 promotes both the proapoptotic pathway and postapoptotic events. DD1a functions as an engulfment ligand that engages in homophilic intermolecular interaction at intercellular junctions of apoptotic cells and macrophages. DD1a-deficient mice showed in vivo defects in clearing dying cells that led to damage to multiple organs indicative of immune dysfunction. p53-induced expression of DD1a is a vital phase for the phagocytic engulfment process of dead cells and then facilitates the stepwise priming of immune surveillance. As a downstream target of the tumor suppressor p53, DD1a activation may extend the repertoire of p53 activities to "guardian of the immune integrity." 
D
uring development, tissue restoration, and response to injury, numerous cells are damaged and destined to undergo cell death or apoptosis. Thus, rapid and efficient clearance of cell corpses is a vital prerequisite for homeostatic maintenance of tissue health (1, 2) . Failure to clear dying cells can lead to the accumulation of autoantigens in tissues that foster diseases, such as chronic inflammatory diseases, autoimmune diseases, and developmental abnormalities (1) (2) (3) (4) . Engulfment of apoptotic cells is an active process coordinated by receptors on phagocytes and ligands on apoptotic cells (5) . The exposure of phosphatidylserine (PtdSer) on the surface of dying cells is a key signal that facilitates recognition and clearance by neighboring phagocytes (6) . PtdSer on apoptotic cells can be recognized directly by phagocytic receptorssuch as T-cell immunoglobulin and mucin domain-1, -3, and -4 (TIM-1, TIM-3, and TIM-4); brain-specific angiogenesis inhibitor 1 (BAI1); and Stabilin-2-or indirectly via soluble bridging proteins [milk fat globule-EGF-factor 8 (MFG-E8) and complement component (C1q)] to engage in engulfment of apoptotic cells (7) (8) (9) (10) (11) (12) (13) .
The p53 tumor suppressor is indispensable for maintenance of genomic integrity (14) (15) (16) . p53 functions as a transcription factor that is activated by various cellular stresses and governs multiple core programs in cells, including cell cycle arrest and apoptosis (17, 18) . p53 has been implicated in immune responses and inflammatory diseases (19) (20) (21) (22) . Several interferon (IFN)-inducible genes-such as interferon regulatory factors 5 and 9 (IRF5 and IRF9), interferonstimulated gene 15 (ISG15), and Toll-like receptor 3 (TLR3)-are also p53 targets (20, (23) (24) (25) . Among others, it has been reported that the expression of forkhead box P3 (Foxp3), a master regulator of regulatory T cells (T regs ), is up-regulated by p53, and the number of T regs was significantly reduced in p53-deficient mice (26, 27) . p53 also stimulates innate immunity by modulating macrophage function to non-cell-autonomously suppress tumorigenesis (28) . Furthermore, although it remains unknown how p53 suppresses autoimmunity and excessive inflammation, accumulating studies have provided convincing evidence that p53 deficiency is closely associated with the development of autoimmune and inflammatory diseases in mice (21, 27, (29) (30) (31) (32) (33) (34) .
Results

Identification of a postapoptotic target gene of p53, DD1a, an immunoglobulin superfamily receptor
Through microarray analysis of cDNA expression in EJ-p53 human bladder tumor cells with a tetracycline-regulated wild-type p53 (Wt-p53) overexpression system (35), we identified the gene encoding a transmembrane receptor, Death Domain1a (DD1a), as a downstream target gene of p53. DD1a mRNA and protein abundance were increased in response to genotoxic stress in a p53-dependent manner (Fig. 1A and figs. S1 and S2). The characterization of candidate p53 DNA binding consensus sequences by using reporter gene assays, chromatin immunoprecipitation-quantitative realtime polymerase chain reaction (ChIP-qPCR) and electrophoretic mobility-shift assay indicated that DD1a was a direct transcriptional target of p53 and that a consensus p53-binding site located at -5401 to -5420 of the DD1a promoter conferred p53-dependent DD1a transactivation (Fig. 1B) . DD1a is a member of the immunoglobulin superfamily and is also known as Gi24 or VISTA or PD-1H or Dies1 (36) (37) (38) (39) . The DD1a protein migrated at 50 kD on Western blots. Treatment of cells with the glycosylation inhibitor tunicamycin resulted in migration at~30 kD, its predicted size ( fig. S3 ). Northern blotting of various human tissues demonstrated relatively higher expression of DD1a in blood leukocytes, placenta, spleen, and heart and low amounts in lung, kidney, small intestine, and brain (Fig. 1C) . Analysis of public database information (http://biogps.org/#goto=genereport&id=64115) (40, 41) also indicated that DD1a is expressed in immune cells, including macrophages, dendritic cells, monocytes, and myeloid and T cells. Although we identified DD1a as a bona fide p53 target gene, the depletion of endogenous DD1a by short hairpin RNAs (shRNAs) targeting different sequences in DD1a mRNA did not affect the DNA damage-induced apoptotic responses (figs. S4, S5C, S6, and S7B) in various cell systems carrying Wt-p53, which suggests that DD1a may not function as a typical p53 target gene. DD1a has similarity with several members of the immunoglobulin superfamily with the immunoglobulin variable (IgV) domain (Fig. 1C) . We sought to determine whether TIM family proteins, as well as immune checkpoint coinhibitors, programmed cell death 1 (PD-1), and programmed death-ligand 1 (PD-L1), might be regulated by p53 as seen for DD1a. The TIM family proteins, including TIM-1, TIM-2/3, and TIM-4, did not show increased expression in response to p53, but genes encoding PD-L1 and its receptor PD-1 showed increased expression in response to the p53 activator Nutlin-3 small molecule (10 mM) in MCF7 human breast cancer cells (Fig. 1D) . Genotoxic stimuli also activated transcription of PD-L1 and PD-1 in a p53-dependent manner. We verified p53-mediated activation of PD-L1 or PD-1 expression in several p53 expression systems (Fig. 1D ).
p53-induced expression of DD1a is essential for engulfment of apoptotic cells by phagocytes TIM family molecules have an important role in phagocytosis of apoptotic cells (8, 9, 11) . Because DD1a is structurally similar to TIM family proteins, we investigated whether increased abundance of DD1a induction on apoptotic cells could proceed to phagocytosis of dying cells. We depleted 1261669-2 31 JULY 2015 • VOL 349 ISSUE 6247 sciencemag.org SCIENCE Fig. 1 . Identification of DD1a as a p53 target gene. (A) p53-dependent expression of DD1a. DD1a mRNA and protein were assessed after tetracycline (tet) removal in EJ-p53 tet cells (tet-off) (top). MCF7 cells (bottom) were transfected with either siRNA targeting p53 or luciferase control for 24 hours, then treated with CPT (500 nM). MCF7 cells were treated with Nutlin-3 (10 mM) for the indicated times. Northern blots were used to determine mRNA expression of p53, DD1a, p21, and 36B4. Western blotting was performed with specific Abs against p53, DD1a, p21, and b-actin. (B) p53 binds to and transactivates the DD1a promoter. Luciferase reporter constructs containing the putative p53 recognition sites in the DD1a promoter were cotransfected with either Wt-p53, mutant p53 (V143A), or pcDNA3.1 empty vector into U2OS cells. Results represent mean T SD from three experiments. ChIP was performed on MCF7 cells exposed to IR (13 Gy). Immunoprecipitation was carried out with Ab against p53 (DO-1) or mouse IgG (negative control). The % input of coprecipitating DNAs was measured by qPCR and presented as mean T SD (n = 3). (C) The expression of human DD1a mRNA was analyzed by Northern blotting from various human tissues, including blood leukocyte (Lk), lung (Lu), placenta (Pl), small intestine (SI), liver (Li) , kidney (Ki), spleen (Sp), thymus (Tm), colon (Co), skeletal muscle (Sm), heart (He), and brain (Br). Multiple sequence alignment of the IgVdomains of DD1a and its homologous proteins.The predicted secondary structures are shown below the alignment as blue e for b strand and red h for a helix.The identical amino acids are in red box, the conserved amino acids are in yellow box, and the consensus amino acids are in green box. (D) p53-dependent expression of immune checkpoint regulators PD-1 and PD-L1. MCF7 cells were treated with 10 mM Nutlin-3 for 1 to 3 days. MCF7 cells were transfected with control siRNA or p53 siRNA for 24 hours and treated with 500 nM CPTor DMSO for 1 or 2 days.The levels of indicated proteins (TIM-1, TIM-3, TIM-4, PD-L1, and PD-1) were analyzed by Western blot analysis. Total RNAs from control siRNA or p53 siRNA transfected MCF7 cells were assessed for mRNA levels of PD-1 or PD-L1 by real-time quantitative PCR. PD-1 or PD-L1 mRNA levels were normalized to 36B4 expression and shown as mean T SD (n = 3). ZR75-1 cells treated with 500 nM CPT or A375 cells exposed to IR (13 Gy) for indicated times.
DD1a and p53 expression in MCF7 cells exposed to the apoptotic stimulus camptothecin (CPT) with two different DD1a shRNAs or p53 shRNAs ( fig.  S4A ). About 60% of MCF7 cells expressing shluciferase (control), sh-DD1a, sh-p53, or both sh-DD1a and si-p53 were apoptotic after CPT treatment ( fig. S4B ). We used a pH-sensitive dye (pHrodo), which emits red fluorescence only when located in the phagosome (pH~5), to distinguish engulfed cells from unengulfed cells, and we calculated the phagocytic index (number of ingested cells per 100 macrophages) (42) . To examine the functional role of DD1a or p53 in engulfment of dead cells, we used freshly isolated human monocyte-derived macrophages (hu-MDMs) and measured engulfment of CPT-treated apoptotic MCF7 cells. When control apoptotic MCF7 cells were incubated with hu-MDMs, the phagocytic index was~50 or higher ( Fig. 2A) , which indicated that macrophages efficiently engulfed most of the apoptotic MCF7 cells present. However, when DD1a-or p53-depleted MCF7 cells, or MCF7 cells depleted of both, were mixed with hu-MDMs, macrophages engulfed a lower number of apoptotic cells (phagocytic index of 10 to 25 for DD1a-depleted,~30 for p53-depleted, and 10 to 25 for both p53 and DD1a-depleted) ( Fig. 2A) . Reexpression of DD1a in DD1a-depleted MCF7 cells restored engulfment amounts to similar to those of control cells ( Fig. 2A) . ZR75-1 human breast cancer cells with Wt-p53 were also used to carry out the phagocytosis assay. Consistent with the behavior of MCF7 cells, when apoptotic ZR75-1 cells were incubated with hu-MDMs, DD1a or p53 depletion also decreased engulfment by macrophages ( fig. S5 ). We also used two human cancer cell lines (BxPC-3, human pancreatic cancer cell line; and Hs888.T, human osteosarcoma cell line) that had very low DD1a expression, and we found that expression of DD1a was not increased by CPT (Fig. 2B, right) . Apoptotic cells of both BxPC-3 and Hs888.T were less efficiently engulfed by huMDMs than by DD1a-expressing cell lines, such as MCF7, ZR75-1, and A375 (human melanoma cell line) (Fig. 2B, left, and fig. S6 ). However, ectopic expression of DD1a-HA in BxPC-3 and Hs888.T cells restored engulfment of dead cells by macrophages, which suggested that DD1a expression was sufficient to promote apoptotic cell engulfment by phagocytes (Fig. 2B) .
We further examined the effects of p53 or DD1a deficiency on the phagocytosis of apoptotic cells with genetically modified mouse cells. Thymocytes isolated from wild-type (Wt), DD1a -/-, and p53
-/-mice were exposed to ionizing ra- thymocytes by macrophages ( Fig. 2D and movies S1 to S3). Together, these data demonstrate that the p53-induced accumulation of DD1a is required for engulfment of apoptotic cells by phagocytes.
Impaired clearance of apoptotic cells in the DD1a-deficient mice
We tested whether DD1a deficiency caused defects in dead cell clearance in vivo in DD1a-deficient mice. DD1a -/-mice were generated using the Flp-Cre system, and DD1a deficiency was confirmed in vivo ( fig. S8 ). In mice with total body exposure to IR, thymocytes undergo apoptosis and are rapidly cleared by phagocytes. Whereas Wt mice showed a decrease in overall thymic size because of dead cell removal after IR exposure, DD1a -/-mice showed less of a reduction in thymic size after IR exposure (Fig. 3A , top left). Quantification of cell numbers confirmed that IRexposed DD1a -/-mice retained a larger thymic cell population than did control mice (Fig. 3A , bottom left). We observed similar changes in the spleen, another radiosensitive organ. IR clearly decreased the spleen size and weight of Wt mice, but DD1a -/-mice showed significantly less size reduction after IR (Fig. 3B ). We also examined the presence of apoptotic cells in whole mounts of thymus at different times after IR exposure, by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining. Quantification of TUNELstained cells was calculated as a fraction of DAPI (4′,6-diamidino-2-phenylindole)-positive cells using an imaging analysis program. In Wt and DD1a
-/-mice, irradiation of thymocytes with IR induced a similar extent of apoptosis at 3 hours (~40%) and 6 hours (more than 80%). After 6 hours, apoptotic cells in Wt thymus were rapidly cleared down to 40% at 12 hours and 20% at 18 hours. However, the clearance of apoptotic cells in DD1a -/-thymus was delayed, with twice as many apoptotic cells remaining in DD1a -/-thymus as in Wt thymus (Fig. 3A, right) . Thus, DD1a functions in apoptotic corpse clearance in vitro and in vivo. Because apoptotic cells are typically cleared rapidly in vivo, they are rarely detectable histologically. We thus examined whether DD1a -/-mice displayed defects in scavenging apoptotic cells by TUNEL staining of tissue sections. In lymph nodes and colons, we observed 7-to 8-fold and~17-fold increases, respectively, in TUNEL-positive cells in sections from DD1a -/-mice as compared with sections from Wt animals ( Fig. 3C ). We asked whether DD1a also affected the phagocytic removal of apoptotic cells in a p53-independent manner in vitro and in vivo. Treatment of dexamethasone (Dex) induces prompt and synchronous p53-independent cell death, and the consequent removal of apoptotic cells by phagocytes can provide a quantitative experimental model of apoptotic cell clearance in vitro and in vivo (43) (44) (45) Total cell numbers per thymus from Wt and DD1a -/-mice were determined at 8 hours after ionizing irradiation. Mean T SD, n = 4 per group. **P < 0.01 (Tukey's test).The right panels represent whole sections of thymus from Wt and DD1a -/-mice exposed to IR that were stained with TUNEL (red) and 4′,6-diamidino-2-phenylindole (DAPI; blue). S9C ). We also showed that there were no obvious differences in the steady-state levels of DD1a expression in multiple tissues between Wt and p53-null mice ( fig. S10 ). Thus, DD1a functions in apoptotic corpse clearance by both p53-dependent and independent ways in vitro and in vivo, and phagocytic engulfment of apoptotic cells is impaired in the absence of DD1a.
DD1a expression in macrophages is required for engulfment of apoptotic cells
DD1a is highly expressed on blood leukocytes (Fig. 1C ) and in macrophages ( fig. S11 ) and dendritic cells (37, 38) . Because of the expression of DD1a in phagocytes, we investigated whether DD1a expression in macrophages is also necessary for the engulfment of apoptotic cells. We used Wt-or DD1a-null thymocytes as prey and incubated them with Wt or DD1a -/-m-BMDMs for quantification of phagocytosis analysis using flow cytometry (Fig. 4A) . DD1a -/-m-BMDMs were deficient in uptake of pHrodo-labeled apoptotic Wt thymocytes, as compared with Wt m-BMDMs, but showed a similarly diminished engulfment rate when DD1a-null apoptotic thymocytes were used as prey. Phagocytosis analysis of Wt-and DD1a -/-m-BMDMs with synthetic beads (Fig.   4B ) or bacteria (E. coli) (Fig. 4C ) further revealed that DD1a -/-m-BMDMs have no defect in phagocytic ability, which suggests that DD1a-mediated engulfment is dependent upon the presence of DD1a in apoptotic cells but that engulfment of DD1a-independent targets is not. Thus, DD1a participates on both apoptotic cells and macrophages for engulfment of apoptotic cells.
PtdSer-independent engulfment of apoptotic cells by DD1a
Dying and/or apoptotic cells expose PtdSer on the outer leaflet of the surface membrane of apoptotic cells, which is considered a primary signal recognized by PtdSer receptor of phagocytes (1, 4 S15A) . We also performed a proximity ligation assay using Duolink in situ fluorescence assay to detect the association of DD1a-DD1a molecules between two different cell types, J774.1 (macrophage) and ZR75-1 (breast carcinoma cell). (Fig. 5D ). To test whether soluble DD1a-Ig proteins compete or cooperate for intercellular DD1a-DD1a binding, we preincubated Jurkat-DD1a cells with soluble DD1a-Ig or Ig proteins. We found that exogenous treatment of DD1a-Ig modestly inhibited DD1a-DD1a-mediated intercellular binding between two differently labeled Jurkat/DD1a cell populations (Fig. 5D) . We mapped the binding region for DD1a-DD1a binding by in vitro binding analysis using glutathione S-transferase (GST)-and histidine (His)-fused DD1a variants and observed that the extracellular (amino acids (Fig. 5E ). Cross-linking experiments using GST-fused DD1a variants also revealed self-association of the DD1a extracellular domain in solution (Fig. 5F, left) . Cross-linked dimers were observed with the DD1a extracellular domain variant in solution but not with the cytoplasmic region of DD1a. Dimerization of DD1a was also examined in intact cells (293T). DD1a-transfected cells were incubated with or without bismaleimidohexane (BMH), another cross-linker for covalent conjugation between sulfhydryl groups. The formation of the DD1a dimer was detected on nonreducing gels after treatment of cells with BMH (Fig. 5F, right) .
We (Fig. 5G) . To elucidate the possibility of the cis-dimerization for the DD1a-DD1a interaction, we performed a proximity ligation assay using the Duolink technology to detect the association of DD1a-DD1a molecules within the same cell. Colocalization dots were detected only in 293T cells overexpressing both DD1a-HA and DD1a-Myc ( fig. S17) 
-/-mice (Fig. 6A) . A majority of female DD1a -/-mice had ulcerative dermatitis and 35%, 23%, and 12% of female DD1a -/-mice showed otitis, eye-related inflammation, and seizures, respectively (Fig. 6A) . Impaired clearance of apoptotic cells and accumulated corpses of dead cells can cause susceptibility to autoimmune disease (1, 3, 4) . Because DD1a −/− mice showed severe skin inflammation (Fig. 6B) , which is one of the clinical manifestations of systemic autoimmune disease, we examined whether DD1a
-/-mice showed increased autoantibody titers. Starting at 8 to 10 months of age, the abundance of antinuclear antibodies (ANA) was increased in the sera of the phenotypically affected female DD1a
-/-mice ( Fig. 6C and fig. S18 ). Additionally, Abs to double-stranded DNA (dsDNA) were found in the serum from DD1a -/-mice (Fig. 6C) . Furthermore, total immunoglobulin G (IgG) in sera from 10-month-old phenotypically affected DD1a -/-female mice was increased to~6-fold in comparison with that of age-matched Wt mice (Fig. 6C) .
One of the most commonly targeted organs in systemic autoimmune disorders is the kidney (50) . Consistent with other evidence of autoimmune activity, in the renal glomeruli of DD1a -/-mice, we observed immune complex deposition identified by immunofluorescence (Fig. 6D ) and diffuse mesangial expansion as shown by periodic acid-Schiff (PAS)-positive material and cellular debris (Fig. 6D) . Electron microscope analysis also showed an expanded mesangium with electrondense deposits and neutrophils within capillary lumens of DD1a -/-mice (Fig. 6D) . Numerous large electron-dense deposits were also observed in electron micrographs of the glomerular mesangium of DD1a -/-glomeruli (Fig. 6D) . Consistent with the above kidney phenotypes, DD1a -/-mice produced large amounts of protein in their urine (Fig. 6C) mesangioproliferative pattern of injury and immune complex deposition. We observed extensive splenomegaly and lymphadenopathy in DD1a -/-mice by 10 months of age (Fig. 6E) . Further histological analysis revealed extensive inflammatory infiltrates in skin and lung, and extramedullary hematopoiesis, including both erythroid and myeloid hyperplasia, was evident, which indicated a major immune dysregulated phenotype of DD1a -/-mice ( fig. S19 ).
Inhibitory role of functional DD1a-DD1a interaction in T cell activation
Given the functional and biochemical homophilic DD1a-DD1a interaction between dead cells and macrophages, we next sought to determine whether such an interaction could also occur with naturally expressed DD1a on T cells. S20B ). Expression of DD1a on antigen-presenting cells (APCs) functions as a negative regulator or ligand of T cell response in vitro and its overexpression on tumor cells interferes with protective antitumor immunity in mice (37, 51) . DD1a is also expressed on T cells and can function as a coinhibitory receptor of T cell activation (38, 49, 52) . Moreover, preclinical studies with blocking Abs to DD1a enhanced antitumor T cell responses, leading to inhibited tumor growth and better survival (51 Engagement of DD1a-Ig inhibited CD3 Ab-induced proliferation of CD4 + or CD8 + T cells (~50% inhibition). However, DD1a
-/-CD4 + or CD8 + T cells were less sensitive to DD1a-Ig (~30% inhibition) ( fig. S22 ), although DD1a deficiency did not prevent inhibition completely. These data indicate that potential homophilic DD1a interactions are important for the DD1a-mediated T cell inhibitory role and that DD1a functions as a receptor on T cells. These findings indicate a role for tumor suppressor p53 in regulating expression of immune regulators, including PD-1, PD-L1, and DD1a, which suggests a potential role of p53 in immune responses.
Discussion
Our findings reveal that the tumor suppressor p53-induced expression of DD1a regulates efficient clearance of dead cells and proper immune tolerance. Although these two essential activities are seemingly interrelated, the complexity of these processes is demonstrated by the many receptors and signaling pathways involved in the recognition and removal of apoptotic cells by macrophages and stringent discrimination of self antigens from nonself antigens (1, 53, 54) . We found that DD1a is a receptor that engages in homophilic intermolecular interaction or dimerization at intercellular junctions of apoptotic cells and macrophages, which is critical for the engulfment of apoptotic cells. Mice deficient in scavenger receptors develop spontaneous autoimmune disease (55) (56) (57) (58) , whereas deficiencies in dead cell clearance do not always elicit autoimmunity because these apoptotic cells in these deficiencies are still able to trigger a downstream immunosuppressive signal to inhibit autoimmunity (59, 60) . In a normal immune system, phagocytic engulfment of apoptotic cells is accompanied by induction of a certain degree of immune tolerance in order to prevent self-antigen recognition (53, 61) .
At age 10 to 12 months after birth, DD1a-deficient mice showed autoimmune phenotypes predominantly in female mice. These results imply that DD1a seems to be critical in dead cell clearance, and its loss directly affects immune tolerance. Previously reported DD1a knockout mice were generated by a gene-trapping approach targeting coding exon 1 (48) . We achieved a Cremediated complete deletion of exons 2 and 3 of the DD1a gene, which resulted in the development of similar and yet exaggerated phenotypes with moderate to severe increases in size of certain organs and prominent formation of immune infiltrates in the skin, lung, liver, and kidney. Notably the autoimmune defects observed in the aged female DD1a mice were apparent even in the absence of other predisposing factors and resulted in an increased late mortality rate in females. Interestingly, the autoimmune phenotype characteristic for late-stage DD1a knockout animals is clearly prevalent in female mice. Importantly, similar gender bias has been previously described for various animal models of autoimmune disorders, such as SLE in which female animals are significantly more susceptible to the disease (55, 62) . Also, sex hormones have been previously implicated in the development of high-affinity auto-reactive B cells (63) . Epidemiological studies in humans also show extremely high (9:1) gender bias toward females for systemic autoimmune diseases (64) .
The process of apoptotic-cell clearance involves extensive numbers of molecules. Based on resulting phenotypes of various knockout mice, it has been suggested that some molecules are critical for proper cell turnover during development (e.g., PSR, Beclin1, Atg5) (65) (66) (67) , and other molecules are essential in the adult life, when rates of apoptosis in relevant tissues are physiologically normal during tissue homeostasis or when rates of apoptosis are accelerated under various stress stimuli (e.g., MFG-E8, TIM-4, SCARF1, C1q, CD14, Mer) (55-58, 68, 69) . Our data indicate that DD1a primarily responds to apoptotic stress and is more likely to be involved in the regulation of engulfment and phagocytosis of dead cells on the sites of extensive damage because of exogenously induced cellular toxicity. Additionally, public database information [EMAGE gene expression database (http:// www.emouseatlas.org/emage/)] shows that DD1a is almost not detectable at the embryonic stage, whereas PSR or Beclin1, which are involved in cell turnover during development, are markedly expressed in the embryo (70) . Therefore, DD1a deficiency leads to accumulative defects of cellular clearance over prolonged time and results in an age-dependent autoimmune phenotype, which suggests the specific role of DD1a in a stress-responsive environment.
DD1a is expressed in immune cells, including macrophages and T cells, and likely functions as a receptor through DD1a-DD1a binding at intercellular junctions. We further demonstrated that DD1a has an important role as an intercellular homophilic receptor on T cells, which suggests that DD1a is a key-connecting molecule linking postapoptotic processes to immune surveillance. DD1a also appears to inhibit T cell activation. These findings establish a concept for cancerdriven control of immune surveillance: p53-dependent genotoxic stress-mediated expression of DD1a and related immune checkpoint inhibitors, such as PD-1 and PD-L1 molecules on cancer cells, may enable their interactions with T cells in order to impose suppression of the immune response and escape from immune surveillance.
Materials and methods
Plasmids, transfection, and lentiviruses
For mammalian expression vector, full-length human DD1a cDNA was subcloned into pcDNA3.1(-) tagged with HA or Myc at the C terminus using standard procedure. Immunoglobulin V domain (amino acids 45-168)-deleted mutant DD1a-DIgV was generated by a PCR-mediated deletion method. For Fc-tagged soluble DD1a proteins (DD1a-Ig), the extracellular region of DD1a was cloned upstream of the mouse IgG-Fc region , DD1a (37-146), DD1a-DIgV (33-311, DIgV), and DD1a (215-311) were generated by PCR and subcloned into pGEX-6P-1 (GE Healthcare Life Sciences, Pittsburgh, PA). DD1a was amplified and subcloned into pRSET vector (Invitrogen, Life Technologies, Grand Island, NY). For GST-fused p53 (93-312), p53 (93-312; DNA binding domain) was subcloned into pGEX-6P-1 (GE Healthcare Life Sciences). Transfections were performed using Lipofectamine 2000 (Invitrogen). Plasmids encoding lentivirus expressing DD1a-HA were generated by cloning DD1a-HA into pLenti CMV Neo DEST. Cells were transduced with lentivirus in the presence of polybrene. Infected cells were selected in complete appropriate medium containing 10% fetal bovine serum (FBS) and G418 and were tested 1 week after infection. shRNA and siRNA experiments Plasmids (pLKO.1-puro) expressing shRNAs against human DD1a-1 (5′-GCAGAGACAACTTCTAAGAAT-3′; TRCN0000145473, Sigma-Aldrich) and DD1a #2 (5′-GCACGATGTGACCTTCTACAA-3′; TRCN0000140372, Sigma-Aldrich) and pLKO.1-puro Luciferase shRNA Control Plasmid DNA (Sigma-Aldrich) were purchased. p53 siRNA (Validated Stealth RNAi siRNA, oligo ID: VHS40367) and control siRNA (Stealth RNAi Negative Control Low GC) were purchased from Invitrogen. shRNA plasmids and siRNAs were introduced into cells by transfection using Lipofectamine 2000 (Invitrogen) or X-tremeGENE siRNA Transfection Reagent (Roche), respectively. MCF7 or ZR75-1 cells stably expressing shRNAs were generated by selection with puromycin (1.0 mg/ml for MCF7, 1.25 mg/ml for ZR75-1).
Antibodies and additional reagents
RNA analysis
RNA was prepared with TRIzol Reagent (Invitrogen) according to the manufacturer's protocol. Total RNAs of human tissues were purchased from Clontech. The RNAs were analyzed by the Northern blot analysis as described previously (74) . For real-time qPCR analysis, total RNAs were extracted with the Qiagen RNeasy kit with QIAshredder. cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). Primers were as follows: For human: DD1a: 5′-GATGTGACCTTCTACA-AGACG-3′ and 5′-GTCCTGGAACGTGAGGTTGC-3′; PD-1: 5′-CCAGGATGGTTCTTAGACTCCC-3′ and 5′-TTTAGCACGAAGCTCTCCGAT-3′; PD-L1: 5′-TGGCATTTGCTGAACGCATTT-3′ and 5′-TGCAGCCAGGTCTAATTGTTTT-3′; RPLP0: 5′-CAGATTGGCTACCCAACTGTT-3′ and 5′-GGG-AAGGTGTAATCCGTCTCC-3′. For mouse: DD1a: 5′-GGAACCCTGCTCCTTGCTATT-3′ and 5′-TTGTA-GATGGTCACATCGTGC-3′; Rplp0: 5′-TCGGGTCCTA-GACCA-3′ and 5′-AGATTCGGGATATGCTGTTGGC -3′. qPCR analysis was performed using an Icycler IQTM5 real-time system (Bio-Rad) with SYBER Green (Roche) for detection. Expression levels of genes analyzed by qPCR were normalized relative to levels of human RPLP0 or mouse Rplp0 expression.
Reporter plasmid generation and luciferase assay
A portion (1.7 kb) of the human DD1a promoter region was amplified by PCR and digested with SacI and XhoI and then was subcloned into luciferase expression vector (pGL4.21[luc2P/Puro], Promega). Transcription start site is marked as +1. For 6-kb promoter-report construct, the upstream of DD1a promoter from 1.7 kb to 6 kb was amplified by PCR and digested with KpnI and SacI, and then ligated into 1.7-kb DD1a promoter-luciferase construct. All constructs are verified by DNA sequencing. For luciferase assay, the luciferase reporter plasmids were transfected into cells. Vector encoding Renilla (pRL-TK) was also cotransfected for normalization of the transfection efficiency. The luciferase activity was determined using the Dual Luciferase Reporter Assay System (Promega).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation of IR-exposed MCF7 cells was performed following the manufacturer's protocol (Upstate). Immunoprecipitation was carried out at 4°C overnight with polyclonal Ab against p53 and mouse IgG (Santa Cruz) as a negative control. Immunoprecipitated DNA was analyzed by qPCR with the following primers.
DD1a-BS1: 5′-ATATAGCAAGACCCCACCTCTACA-3′, 5′-CACAGTGCAGCAACAAATAGAAGT-3′ DD1a-BS2: 5′-CCTCAGGCTCTGAATCTACAGT-TA-3′, 5′-GGGACAGAGACTTGTACCCTACAT-5′ p21: 5′-CTCACATCCTCCTTCTTCAG-3′, 5′-CAC-ACACAGAATCTGACTCCC-3′
The amount of immunoprecipitated DNA was normalized to inputs.
Electrophoretic mobility-shift assay
After etoposide treatment, nuclear extracts were collected from MCF7 cells using a general nuclear extraction method. Nuclear extracts (5 mg) or purified recombinant p53 was incubated with 32 P-labeled oligonucleotides in gel shift binding buffer (5 mM Tris-HCl at pH 7.5, 20 mM NaCl, 0.5 mM MgCl 2 , 0.25 mM EDTA, 0.2% NP-40, 2.5% glycerol, 1 mM DTT, 20 mg/ml BSA, and 40 mg/ml poly(dI-dC). The DNA-protein complexes were resolved by electrophoresis through 5% polyacrylamide gel containing 0.5% TBE. Gels were dried and exposed to X-ray film. Unlabeled wildtype oligonucleotide or unlabeled mutant oligonucleotide was added in 100-fold excess as specific or nonspecific competitor. Oligonucleotides corresponding to the DNA binding consensus sequence for human p53 (75, 76) were used. DD1a-BS1: 5′-GCTGGGCATGGTGGTGCAT-GCCTGTA-3′ DD1a-BS1 Mut: 5′-GCTTTTTGCAGAGGTGT-CAAAGGTA-3′ DD1a-BS2: 5′-GTTAAACTGGCTCCAGCTTG-CCTAGC-3′ p21-BS: 5′-TGTCCGGGCATGTCCGGGCATGT-CCGGG-3′ p21-BS Mut: 5′-TGTCCGGGAATTTCCGGGAA-TTTCCGGG-3′
Preparation of human and mouse macrophages
For hu-MDM, human peripheral blood mononuclear cells were prepared from normal blood obtained from the Massachusetts General Hospital blood donor center (protocol number 2012P002174). Monocytes were isolated by adhering mononuclear cells to culture plates for one hour at 37°C, after which nonadherent cells were removed by washing. The remaining cells were >95% CD14 positive.
Adherent cells were then incubated in DMEM/F12 medium plus 10% FBS, 1% penicillin-streptomycin for 7 days to allow terminal differentiation of monocytes to macrophages (77) . For mouse bone marrowderived macrophages (m-BMDM), femurs and tibias were harvested from 5-to 6-week-old mice and the marrow was flushed and placed into a sterile suspension of PBS. The bone marrow suspension was cultured in DMEM/F12 medium plus 10% FBS, 1% penicillin-streptomycin-glutamine with 40 ng/ml recombinant murine macrophage colony-stimulating factor (M-CSF, Peprotech). Six days later, more than 90% of the adherent cells were CD11b positive and 80% of the cells were F4/80 positive.
Generation of apoptotic cells
Apoptosis of human cancer cells was induced by CPT (0.5 to 20 mM). To generate apoptotic thymocytes, thymocytes isolated from mice were exposed to the indicated dose of IR with constant cell concentration of 1.0 × 10 6 thymocytes/ml. For phagocytosis assays, apoptotic cells were labeled with pHrodo or CFSE (carboxyfluorescein diacetate succinimidyl ester) (Invitrogen). Cells were used when 60 to 70% of cells were apoptotic, as defined by annexin V-positive and propidium iodide-negative staining or TUNEL staining by flow cytometry.
Phagocytosis assay
For flow cytometry analysis of phagocytosis, 2.0 × 10 5 BMDMs were plated in the 24-well plate 1 day before the phagocytosis assay. Next day, the cells were starved for 30 min with DMEM/F12 containing 2% FBS and incubated with fluorescently labeled targets, such as 4.0 × 10 6 pHrodo (Invitrogen)-stained apoptotic thymocytes, 1 mg/ml pHrodo Red E. coli BioParticles (Invitrogen), or 2-mm carboxylate-modified latex beads (Invitrogen) in 150 ml of the uptake buffer (DMEM/F12 containing 2% FBS, 0.2% penicillin-streptomycin). After incubation for the indicated time, the cells were extensively washed with cold PBS, trypsinized and resuspended in cold medium containing 1% NaN 3 , and analyzed by flow cytometry. Forward and side-scatter parameters were used to distinguish unengulfed targets from phagocytes. The data were analyzed using FlowJo software. Fluorescent signalpositive BMDMs were considered to be phagocytes engulfing targets (78) . For time-lapse image analysis of phagocytosis, CFSE (Invitrogen)-labeled apoptotic thymocytes were added to BMDM with 1:5 ratio (BMDM:thymocyte). The individual BMDMs were monitored by time-lapse confocal microscopy imaging (Nikon Eclipse Ti and Zeiss LSM 510), with images being taken at 1-to 2-min intervals. For image-based analysis of phagocytosis of human cancer cells, human monocyte-derived macrophages (MDMs) were prepared from human peripheral blood and incubated with pHrodo-labeled apoptotic cancer cells with 1:10 to 1:15 ratio (MDM: cancer cell). Two hours after coincubation, wells were washed thoroughly with cold serum-free RPMI five times and examined under a fluorescence microscope (Nikon Eclipse Ti or Zeiss AxioObserver.Z1) using bright field or Texas Red filter set. The phagocytic index was calculated using the following formula: phagocytic index = number of ingested cells/(number of macrophages/100), as described previously (79) . At least 400 macrophages were counted per well. 
Generation and genotyping of
Analysis of apoptotic cell clearance in vivo
Four-to 5-week-old Wt and DD1a -/-mice were exposed to 6.6 Gy of IR or intraperitoneally injected with 250 mg dexamethasone as described previously (44, 45) . At the indicated time points after exposure of IR or injection of dexamethasone, the mice were euthanized and thymuses and spleens were harvested. For quantification of total number of thymocytes in thymus, thymocytes were resuspended with PBS supplemented with 5% FBS. To monitor the TUNEL-positive apoptotic cells in thymus, 6-mm cryosections of whole thymuses were stained using the In Situ Cell Death TMR Red kit and DAPI according to manufacturer′s instructions (Roche). Whole-thymus images were obtained using an automated image stitching method under fluorescence microscope (Olympus FSX100). To quantify the clearance of TUNEL-positive cells, the percentage of TUNEL-positive cells was determined by the percentage of TUNEL-positive cells per DAPI-positive cells using an imaging analysis program (CellSens Dimension, Olympus).
Mouse serologic and urine analysis
The levels of total IgG, ANA, and ant-dsDNA in mouse serum were determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions (Bio-Rad) with mouse serum at a dilution of 1:10 to 1:50. For immunofluorescent analysis of ANA, HEp-2 slides were used. The images were analyzed by fluorescence microscope (Olympus FSX100). For mouse urine analysis, 24 hours albuminuria was measured using metabolic cages. Of note, mice were fed a 5% sucrose drinking solution during the 24 hours analysis in the metabolic cages. Urine (10 ml) was analyzed by SDS-PAGE and Coomassie blue staining. Bovine serum albumin (0.25, 0.5, 1.0, 2.5, and 5.0 mg) served as standard. Signals were quantified using ImageJ software (NIH). Resulting values of the 5 multiplication of the "size of the area" and the "mean gray value" of each albumin standards were used for construction of a standard curve and its associated mathematical function. Values were translated into albumin concentrations and extrapolated to 24-hour urine volume.
Histology and transmission electron microscopy
Organs were fixed by retrograde vascular perfusion with 4% paraformaldehyde in PBS, removed, and immersed in the same fixative for a maximum of 2 days until further processing for histology, immunohistochemistry, or transmission electron microscopy (TEM), as previously described (80) . For immunocomplex analysis, frozen sections were used. 4 mm paraffin-processed formalin-fixed tissue sections were stained with Periodic Acid Schiff (PAS) or hematoxylin/eosin (H&E). Images were taken with an Olympus BX53 microscope with DP72 camera and processed using Adobe PhotoShop software. Ultra-thin 80-nm sections of resinembedded kidney tissue were mounted on copper grids, treated with uranyl acetate and lead citrate, and examined by a pathologist (A.W.) in a blinded fashion using a JEOL 1010 transmission electron microscope (Tokyo, Japan).
Homophilic interaction assay
Protein A/G-purified DD1a-Ig proteins or Ig proteins (control) were covalently coupled to 6 mm blue carboxylated microparticles as recommended by the manufacturers (Polyscience, Inc.). 293T cells were transfected with the plasmids expressing full length DD1a, DD1a-DIgV, or control empty vector as indicated amount per well of six-well culture plates for 24 hours. The transfected cells were incubated with the Ig proteincoated beads in PBS containing 2% FBS at room temperature. After 30 min, unbound beads were washed with cold PBS and cell monolayers in culture media examined under an inverted microscope, and the binding was determined by measuring the optical density (O.D.) at 492 nm (81) .
In situ proximity ligation assay
The assay was performed with the use of a Duolink using PLA Technology (Sigma-Aldrich). J774.1 macrophages and ZR75-1 breast cancer cells were transfected with plasmids encoding DD1a-HA or DD1a-Myc, respectively, for 24 hours. The transfected cells were trypsinized and cocultured on slide glasses in six-well culture plates. After 24 hours, cells were fixed, permeabilized, blocked, and then incubated with rabbit HA-specific Ab and mouse Myc-specific Ab at 4°C overnight. The cells were then subjected to an in situ proximity ligation assay with PLA probes, according to the manufacturer's protocol. All images were taken with a Nikon Eclipse Ti confocal microscope and processed using Adobe Photoshop software with minimal adjustment of brightness or contrast.
In vitro binding assay
His-fused DD1a and GST-fused DD1a variants were purified from bacteria using Ni-NTA agarose (Life Technologies) or glutathione-Sepharose beads (GE Healthcare Life Sciences), respectively. For binding of His-DD1a to Ig fusion proteins (DD1a-Ig, PD-1-Ig, or Ig), Ig-fused proteins were immobilized on protein A/G agarose. The His-fused DD1a protein was incubated at 4°C for 4 hours in a binding buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 5 mM CaCl 2 , 1 mM DTT, 0.1% NP-40, and 100 mg/ml BSA with GST-fused proteins immobilized on glutathione-agarose beads or Ig-fused proteins immobilized on protein A/G. The bound His-fused protein was eluted from the beads and analyzed by SDS-PAGE and Western blot using His-specific Ab.
Protein lipid overlay assay
Membrane lipid strips (Echelon Bioscience) prespotted with 15 different biologically active lipids, at 100 pmol per spot, were purchased. Nonspecific binding of membranes was blocked by incubation for 18 hours with 3% BSA in TBS-T (50 mM Tris at pH 7.4, 0.5 M NaCl, and 0.1% Tween-20). After blocking, membranes were incubated for 2 hours with 2 mg/ml of soluble recombinant proteins, such as DD1a-Ig purified from mammalian cell, DD1a-His purified from yeast, His-DD1a purified from bacteria, and TIM-1-Ig, and then were washed and incubated with indicated Abs, followed by incubation for 1 hour with a horseradish peroxidaselabeled secondary Ab. Binding was detected by chemiluminescent detection.
T cell activation assay
The cell culture plates were coated with CD3-specific Ab (OKT3, eBioscience for human T cells; 145-2C11, eBioscience for mouse T cells) and various concentrations of DD1a-Ig or PD-L1-Ig. The amount of Ig protein was kept constant at 10 mg/ml by the addition of control Ig protein. Mouse CD4 + and CD8 + T cells were purified from splenocytes freshly isolated from mice using CD4 + T Cell Isolation Kit II, mouse or CD8a + T Cell Isolation Kit II, mouse (Miltenyi Biotec). Purity was confirmed to be over 90% by flow cytometry. The T cells were labeled with 1 mM CFSE, quenched by cold FBS, and incubated in plates coated with CD3-specific Ab and Ig proteins. On day 2 after stimulation, supernatant was collected, and cytokines were assayed by ELISA. On day 3, cells were stained with Ab against CD4-APC (RM4-5, eBioscience for mouse CD4 + T cells) or Ab against CD8-APC (53-6.7, eBioscience for mouse CD8 + T cells) and then analyzed for CFSE dilution by flow cytometry.
Binding assay of Ig fusion proteins to T cells
Purified human CD4
+ T cells from freshly isolated PBMCs were stimulated by plate-bound
